 Katherine Tzou
Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2019 | 913 | 1.030 |
Why?
| | Radiosurgery | 3 | 2019 | 299 | 0.690 |
Why?
| | Prostate-Specific Antigen | 4 | 2022 | 150 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2017 | 850 | 0.530 |
Why?
| | Databases, Factual | 2 | 2019 | 1125 | 0.510 |
Why?
| | Radium | 2 | 2022 | 3 | 0.350 |
Why?
| | Salvage Therapy | 6 | 2017 | 127 | 0.340 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 40 | 0.330 |
Why?
| | Bone Neoplasms | 2 | 2022 | 191 | 0.290 |
Why?
| | Melanoma | 2 | 2022 | 620 | 0.210 |
Why?
| | Radiation Injuries | 2 | 2013 | 128 | 0.200 |
Why?
| | Prostatectomy | 4 | 2017 | 97 | 0.190 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 156 | 0.180 |
Why?
| | Aged, 80 and over | 8 | 2019 | 6306 | 0.180 |
Why?
| | Neuroma, Acoustic | 1 | 2019 | 32 | 0.160 |
Why?
| | Dura Mater | 1 | 2017 | 27 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2022 | 636 | 0.140 |
Why?
| | GATA2 Transcription Factor | 1 | 2017 | 12 | 0.140 |
Why?
| | Kallikreins | 1 | 2016 | 28 | 0.140 |
Why?
| | Prognosis | 3 | 2019 | 3315 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2017 | 86 | 0.140 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 9 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 251 | 0.130 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1032 | 0.130 |
Why?
| | MicroRNAs | 1 | 2022 | 600 | 0.130 |
Why?
| | Aged | 9 | 2019 | 18969 | 0.120 |
Why?
| | Glioblastoma | 1 | 2017 | 250 | 0.120 |
Why?
| | Data Collection | 1 | 2018 | 618 | 0.120 |
Why?
| | Prostate | 1 | 2016 | 157 | 0.120 |
Why?
| | Middle Aged | 10 | 2019 | 26605 | 0.120 |
Why?
| | Male | 14 | 2022 | 55396 | 0.110 |
Why?
| | Rectal Diseases | 1 | 2013 | 17 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2022 | 12521 | 0.110 |
Why?
| | Radiotherapy, Conformal | 1 | 2013 | 68 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4392 | 0.110 |
Why?
| | Brachytherapy | 1 | 2013 | 100 | 0.100 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 332 | 0.100 |
Why?
| | Embolization, Therapeutic | 1 | 2013 | 178 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1175 | 0.090 |
Why?
| | Treatment Failure | 1 | 2011 | 330 | 0.080 |
Why?
| | Humans | 16 | 2022 | 114045 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2013 | 504 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2016 | 754 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1356 | 0.080 |
Why?
| | Adult | 6 | 2019 | 30375 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1162 | 0.080 |
Why?
| | Combined Modality Therapy | 3 | 2017 | 1117 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2007 | 182 | 0.070 |
Why?
| | Medulloblastoma | 1 | 2007 | 172 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2017 | 243 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2017 | 521 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2022 | 9049 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2004 | 74 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2004 | 149 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1206 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2004 | 413 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2004 | 184 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2007 | 966 | 0.040 |
Why?
| | Watchful Waiting | 1 | 2019 | 54 | 0.040 |
Why?
| | Risk Factors | 3 | 2017 | 8614 | 0.040 |
Why?
| | Lomustine | 1 | 2017 | 14 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2019 | 150 | 0.040 |
Why?
| | Craniotomy | 1 | 2017 | 68 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1735 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2017 | 281 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2017 | 192 | 0.030 |
Why?
| | Aminoquinolines | 1 | 2016 | 19 | 0.030 |
Why?
| | Ipilimumab | 1 | 2016 | 27 | 0.030 |
Why?
| | Administration, Topical | 1 | 2016 | 137 | 0.030 |
Why?
| | Coloring Agents | 1 | 2016 | 72 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1422 | 0.030 |
Why?
| | Risk Assessment | 2 | 2015 | 2958 | 0.030 |
Why?
| | Contrast Media | 1 | 2017 | 347 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 813 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1078 | 0.030 |
Why?
| | Organs at Risk | 1 | 2013 | 30 | 0.030 |
Why?
| | Organ Sparing Treatments | 1 | 2013 | 31 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2013 | 127 | 0.030 |
Why?
| | Yttrium Radioisotopes | 1 | 2013 | 51 | 0.030 |
Why?
| | Radiation Protection | 1 | 2013 | 34 | 0.030 |
Why?
| | Microspheres | 1 | 2013 | 123 | 0.030 |
Why?
| | United States | 2 | 2019 | 12137 | 0.020 |
Why?
| | Young Adult | 2 | 2019 | 10444 | 0.020 |
Why?
| | Radiography | 1 | 2013 | 803 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.020 |
Why?
| | Female | 5 | 2019 | 59324 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1638 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1690 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2272 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6077 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2314 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1875 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3039 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2764 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 211 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 926 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2004 | 313 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1144 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 17800 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2004 | 1036 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 5038 | 0.010 |
Why?
| | Infant | 1 | 2007 | 7943 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 9114 | 0.010 |
Why?
| | Mice | 1 | 2004 | 14843 | 0.000 |
Why?
| | Animals | 1 | 2004 | 31565 | 0.000 |
Why?
|
|
Tzou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|